reports
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics ...
ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split The combined company will operate as “Oruka Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “ORKA” effective Tuesday, September 3, 2024 WESTMINSTER, Colo., Aug. 29, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced completion of the merger with Oruka Therapeutics, Inc. (“Oruka”) following ARCA’s successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockhold...
ARCA biopharma Provides Update Regarding Special Dividend Amount in Co...
ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics WESTMINSTER, Colo., Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced an update to the previously announced final amount of the special cash dividend (the “Special Dividend”), which will now equal $1.613 per share of ARCA’s common stock, payable on August 28, 2024, to ARCA’s stockholders of record as of August 26, 2024. The Special Dividend was declared by ARCA’s Board of Directors on August 16, 2024, in connection wit...
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection wi...
ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics WESTMINSTER, Colo., Aug. 23, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors (the “Board”) has approved a reverse stock split of ARCA’s common stock at a ratio of 1-for-12. ARCA’s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Global Market on September 3, 2024, under the new name Oruka Therapeutics, Inc. and under the new symbol “ORKA” following the anticipated cl...
ARCA biopharma Declares Special Dividend in Connection with the Propos...
ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics Special dividend estimated to be $1.59 per share Payment of special dividend conditioned upon ARCA stockholder approval of the Proposed Merger with Oruka WESTMINSTER, Colo., Aug. 16, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ: ABIO) (“ARCA”) today announced that its Board of Directors has declared a special cash dividend (the “Special Dividend”) in connection with the previously announced merger (the “Merger”) with Oruka Therapeutics, Inc. (“Oruka”) pursuant to the Agreemen...
ARCA biopharma Announces Second Quarter 2024 Financial Results and Pro...
ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update WESTMINSTER, Colo., Aug. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of directors (the “Board”) of ARCA to conduct a comprehensive review of strategic alternatives. As part of the strategic r...
ARCA biopharma Announces First Quarter 2024 Financial Results and Prov...
ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee of the board of direct...
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement
ARCA biopharma and Oruka Therapeutics Announce Merger Agreement Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations through 2027 Companies to...
ARCA biopharma Announces 2023 Financial Results
ARCA biopharma Announces 2023 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Special Committee (the “Special Committee”) and, in May 20...
ARCA biopharma Announces Third Quarter 2023 Financial Results
ARCA biopharma Announces Third Quarter 2023 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Special Committee and, in May ...
ARCA biopharma Announces Second Quarter 2023 Financial Results
ARCA biopharma Announces Second Quarter 2023 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Special Committee and, in Ma...
ARCA biopharma Announces First Quarter 2023 Financial Results
ARCA biopharma Announces First Quarter 2023 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., April 24, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Directors established a Special Committee and, in Ma...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate...
ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 24, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its f...
James Flynn Joins ARCA biopharma Board of Directors
James Flynn Joins ARCA biopharma Board of Directors WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO) today announced that James Flynn has joined its Board of Directors. “We are pleased to welcome James Flynn to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input on the Company’s Board of Directors, including our process for evaluating strategic options for the Company.” Mr. Flynn is currently a Managing Member and Portfolio Manager of Nerium Capital LLC, an investment adviser he founded in 2021. Nerium...
ARCA biopharma Announces Third Quarter 2022 Financial Results
ARCA biopharma Announces Third Quarter 2022 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 28, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2022 financial results and provided a corporate update. In May 2022, the Company retained Ladenburg Thalmann & Co. Inc. to act as its fin...
ARCA biopharma Announces Second Quarter 2022 Financial Results
ARCA biopharma Announces Second Quarter 2022 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2022 financial results and provided a corporate update. , ARCA’s President and Chief Executive Officer, commented, “We are in the proces...
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors
Jacob Ma-Weaver Joins ARCA biopharma Board of Directors WESTMINSTER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO) today announced that Jacob Ma-Weaver has joined its Board of Directors. “We are pleased to welcome Jacob Ma-Weaver, the managing member of ARCA’s largest shareholder, to our Board,” said Robert E. Conway, Chairman of ARCA’s Board of Directors. “We appreciate his participation and input as we explore and evaluate strategic options for maximizing stockholder value.” Mr. Ma-Weaver is the Managing Member of Cable Car Capital LLC, an investment adviser he founded in 2...
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options...
ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review WESTMINSTER, Colo., May 05, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO) today announced that it has retained Ladenburg Thalmann & Co. Inc. to act as its financial advisor. In April 2022, the Board of Directors established a Special Committee to explore and evaluate strategic options for maximizing stockholder value. Potential strategic alternatives that may be explored or evaluated as part of this process include the potential for an acquisition, merger, business combination or other strategic transaction involvin...
ARCA biopharma Announces First Quarter 2022 Financial Results
ARCA biopharma Announces First Quarter 2022 Financial Results Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., May 02, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update. , ARCA’s President and Chief Executive Officer, commented, “We are in the proce...
ARCA biopharma Establishes Special Committee of the Board of Directors
ARCA biopharma Establishes Special Committee of the Board of Directors WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value. The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committee includes ARCA Board Chairman Robert E. ...
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Cli...
ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial For the entire cohort of COVID-19 hospitalized patients, the pooled lower and higher rNAPc2 dose groups demonstrated a reduction compared to baseline in D-dimer levels of 16.8% versus 11.2% for standard of care heparin which was not statistically significant and consequently did not achieve the study primary endpointThe treatment effects of rNAPc2 and heparin were different in Mild versus Severe categories of an adapted WHO COVID-19 Severity Scale, with generally decreasing D-dimer levels from baseline in Mild...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.